Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alder Biopharmaceuticals

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

- PMLiVE

Amgen says viral melanoma therapy clears phase III trial

OncoVex demonstrates durable response in skin cancer patients

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

Tetra wins Meningitis UK account

Public affairs agency will promote NHS adoption of vaccine 

- PMLiVE

Novartis turns from social networking to apps for trial recruitment

Launches iPhone and Android cancer trial app in the US

- PMLiVE

Incyte says Jakafi patient developed brain virus

Investigation to determine if myelofibrosis drug is linked to PML

Novartis building

Novartis, ThromboGenics’ eye drug Jetrea gets green light in EU

First drug specifically approved for vitreomacular adhesion

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Discount convinces NICE to uphold recommendation for Novartis’ Xolair

Asthma drug now also available for children

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links